-
Product Insights
NewGastrin/Cholecystokinin Type B Receptor – Drugs In Development, 2024
The Gastrin/Cholecystokinin Type B Receptor pipeline drugs market research report outlays comprehensive information on the Gastrin/Cholecystokinin Type B Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Gastrointestinal, and Infectious Disease which include indications of Gastric Cancer, Lung Cancer, Alzheimer's Disease, Dementia, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Helicobacter pylori Infections, and Coronavirus...
-
Product Insights
NewVascular Endothelial Growth Factor B – Drugs In Development, 2024
The Vascular Endothelial Growth Factor B pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, and Oncology which include indications of Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Solid Tumor, and Metastatic Colorectal Cancer. It also reviews key players involved...
-
Product Insights
NewAmine Oxidase [Flavin Containing] B – Drugs In Development, 2024
The Amine Oxidase [Flavin Containing] B pipeline drugs market research report outlays comprehensive information on the Amine Oxidase [Flavin Containing] B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Infectious Disease, Immunology, and Genetic Disorders which include indications of Parkinson's Disease, Alzheimer's Disease, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019...
-
Product Insights
NewCytochrome b 245 Heavy Chain – Drugs In Development, 2024
The Cytochrome b 245 Heavy Chain pipeline drugs market research report outlays comprehensive information on the Cytochrome b 245 Heavy Chain targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Genetic Disorders, Cardiovascular, Central Nervous System, and Infectious Disease which include indications of Chronic Granulomatous Disease, Cardiovascular Disease, Pulmonary Hypertension, Alzheimer's Disease, Epilepsy, and Influenzavirus A Infections. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target CD19 And CD22 For B-Cell Acute Lymphoblastic Leukemia And Lymphoma in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD19 And CD22 For B-Cell Acute Lymphoblastic Leukemia And Lymphoma in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ThisCART19A in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ThisCART19A in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ThisCART19A in B-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Venetoclax in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Venetoclax in B-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zeluvalimab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zeluvalimab in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zeluvalimab in B-Cell Acute Lymphocytic...
-
Product Insights
NewNet Present Value Model: Longeveron Inc’s Lomecel-B
Empower your strategies with our Net Present Value Model: Longeveron Inc's Lomecel-B report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-001 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-001 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-001 in B-Cell Acute Lymphocytic...